Poster Listings Session 57 <strong>CROI</strong> 2013 215 Helix Plays an Important Role in the Viral Release and C De Candia, Gabriel Duette*, C Espada, H Salomon, and M Carobene Inst de Investigaciones Biomed en Retrovirus y SIDA, Univ de Buenos Aires, Consejo Nacional de Investigaciones Cientficas y Tcnicas, Argentina 216 Siriphan Manocheewa* 1 , V Swain1 , E Lanxon-Cookson1 , M Kim1 , D Westfall1 , M Rolland2 , and J Mullins1 1 2 Univ of Washington, Seattle, US and US Military HIV Res Prgm, Henry M Jackson Fndn for the Advancement of Military Med, Rockville, MD, US c Monday, 2:30-4 pm; Hall B2 Session 58–Poster Abstracts Assembly—Putting It All Together 217 Pascal Jalaguier* 1 , R Cantin1 , and M Tremblay1,2 c Tuesday, 2:30-4 pm; Hall B2 Session 60–Poster Abstracts Restriction Factors: APOBEC and Others 228 Valentina Svicher* 1 2 Ctr Hosp Univ de Quebec-CHUL, Canada and Univ Laval, Canada 218 Replication Lillian Kuo*, K Fujii, and E Freed HIV Drug Resistance Prgm, NCI-Frederick, MD, US 1 , C Alteri1 , MC Bellocchi1 , S Fourati2 , D Armenia1 , L Carioti1 , A-G Marcelin2 , V Calvez2 , F Ceccherini-Silberstein1 , C-F Perno1,3 , and DIVA Study Group 1 2 Univ of Tor Vergata, Rome, Italy;; Hosp Pitie Salpietrere, Paris, France;; and 3Natl Inst for Infectious Diseases L Spallanzani, Rome, Italy 229 Chisu Song* 1 , R Levinson2 , L Sutton2 , R Daquila1 , and J Donahue2 1Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US and 2Vanderbilt Univ Sch of Med, Nashville, TN, US 230 Preventing Retroviral Integration But Is Dedicated to Impair K Belanger, M Savoie, J-F Couture, and Marc-Andre Langlois* Univ of Ottawa, Canada 231 Vif-Independent in vivo Escape of HIV from Lethal John Krisko*, F Martinez-Torres, V Garcia, and J Foster Univ of North Carolina at Chapel Hill, US 219 Dual-tagged HIV-1 Provirus Enhances Dynamic Studies of Mingli Qi* 1 , L Ding 1 , and P Spearman 1,2 1 2 Emory Univ, Atlanta, GA, US and 220 Intracellular HIV-1 Budding Jiwei Ding* 1 , L Sun2 , P Du2 , S Cen1 , G Gao2 , and L Su3 1Inst of Med Biotech, Chinese Academy of Med Sci, and Peking Univ Med Coll, Beijing;; 2Inst of Biophysics, Chinese Academy of Med Sci, Beijing;; and 3 232 Computational Identification of Protein Complexes Involved in Cellular Regulation of HIV Infection Reduces the Complexity of the HIV Regulatory Network Kevin Olivieri* Univ of North Carolina at Chapel Hill Sch of Med, US 1 , L Pache1 , S Chanda1 , J Young2 , S Jaeger3 , N Krogan3 , D Emig4 , and T Idekker4 1 2 Sanford-Burnham Med Res Inst, San Diego, CA, US;; Salk Inst, San Diego, CA, US;; 3Univ of California, San Francisco, US;; and 4Univ of California, San Diego, US 233 Comparative Profiling of Deamination Rates and Target Kasandra Belanger*, M Savoie, and M-A Langlois Univ of Ottawa, Canada 221 HIV-1 Virions Incorporate MCM DNA Helicase Which Modulates Viral Replication in the Newly Infected Cells Steven Santos* 1 , Y Obukhov 2 , S Nekhai 2 , M Bukrinsky 1 , and S Iordanskiy 1 1 The George Washington Univ Sch of Med and Hlth Sci, Washington, DC, US and 2 Howard Univ Coll of Med, Washington, DC, US c Monday, 2:30-4 pm; Hall B2 Session 59–Poster Abstracts (see Session 28 on Tuesday for corresponding Themed Discussion) Restriction Factors: Old and New 222 for the Sean Evans* 1 , X Han1,2 , X Zhou1,2 , J Du2 , W Zhang2 , G Wang2 , and X-F Yu1,2 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US and 2 236 in vivo Marcel Ooms* First Hosp of Jilin Univ, China 1 , B Brayton2 , M Letko1 , S Majdak1 , F Hecht3 , J Barbour2 , and V Simon1 1 2 Mt Sinai Sch of Med, New York, NY, US;; Hawaii Ctr for AIDS, Univ of Hawaii at Manoa, Honolulu, US;; and 3Univ of California, San Francisco, US 227 Novel Regulation of SIV Vpx-mediated SAMHD1 Degradation Wei Wei* 1 , H Guo 1 , X Han 1 , X Liu 1 , S Evans 2 , X Zhou 2 , W Zhang 1 , and X-F Yu 2 1 First Hosp of Jilin Univ, Inst of Virology and AIDS Res, China and 2 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 26 20th Conference on Retroviruses and Opportunistic Infections 234 vif Controls Viral Replication Ryan Troyer* 1 , J Thompson1 , J Elder2 , and S VandeWoude1 1 2 Colorado State Univ, Fort Collins, US and The Scripps Res Inst, La Jolla, CA, US 235 Gelsolin Restricts HIV-1 during Early Viral Infection Laura de Armas Rillo*, L Garcia Exposito, S Ziglio, J Barroso Gonzalez, MS Valera, JD Machado, and A Valenzuela-Fernandez Univ of La Laguna, Spain 223 Michael Letko* 1 , M Ooms1 , G Silvestri2 , and V Simon1 1 2 Mt Sinai Sch of Med, New York, NY, US and Emory Univ Sch of Med, Atlanta, GA, US 224 and Virion Incorporation of Human Antiviral Proteins Taisuke Izumi*, R Burdick, W-S Hu, and V Pathak HIV Drug Resistance Prgm, Natl Lab for Cancer Res, NCI-Frederick, MD, US 225 Degradation Sultan Ali* 1 , C Schwartz1,2 , and O Rohr1,2 c Wednesday, 2:30-4 pm; Hall B2 Session 61–Poster Abstracts Macrophage–HIV Interactions: Cell Biology and Treatment 237 Tetraspanin and DC-SIGN Enriched Compartments that Are Erica Johnson*, H Chu, P Spearman, and R Chakraborty Emory Univ and Childrens Hlthcare of Atlanta, GA, US 238 Acutely HIV 1 2 Univ of Strasbourg, France and IUT of Schiltigheim, Strasbourg, France 226 Zeyun Mi*, Q Zhang, J Zhou, J Ding, L Yu, and S Cen Inst of Med Biotech, Chinese Academy of Med Sci, Beijing + Dwayne Baxa* 1 , M Golembieski1 , M Golembieski1 , L Shetron-Rama2 , and N Markowitz1 1 2 Henry Ford Hosp, Detroit, MI, US and Eastern Michigan Univ, Ypsilanti, US 239 of Pre-integration Complexes Gokul Swaminathan*, S Navas-Martin, and J Martin-Garcia Drexel Univ Coll of Med, Philadelphia, PA, US 240 17 through Induction of Interferon- Carley Tasker* 1 , J Ding 1 , M Schmolke 2 , A Rivera-Medina 1 , A Garcia-Sastre 2 , and T Chang 1 1 Univ of Med and Dentistry of New Jersey, Newark, US and 2 Mt Sinai Sch of Med, New York, NY, US
<strong>CROI</strong> 2013 Session 65 c Tuesday, 2:30-4 pm; Hall B2 Session 62–Poster Abstracts Shutting the Door on HIV Entry 241 251 Joseph Casazza*, A Vostal, D Ambrozak, B Hill, E Boritz, I Gong, Geoffrey Ferir*, K Palmer, and D Schols D Douek, and R Koup Rega Inst for Med Res, Univ of Leuven, Belgium Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US c Tuesday, 2:30-4 pm; Hall B2 Session 63–Poster Abstracts (see Session 45 on Wednesday for corresponding Themed Discussion) Transmitted/Founder Viruses 244 Infection in Individuals Infected with Multiple Transmitted/ Hongshuo Song* 1 , F Cai 1 , V Ganusov 2 , J Pavlicek 1 , B Keele 3 , H Li 4 , G Shaw 4 , B Haynes 1 , B Hahn 4 , and F Gao 1 1 Duke Univ Med Ctr, Durham, NC, US;; 2 Univ of Tennessee, Knoxville, US;; 3 SAIC-Frederick Inc, MD, US;; and 4 Univ of Pennsylvania, Philadelphia, US 245 MTCT Is Associated with a Gag-Protease-driven Viral Vanessa Naidoo* 1 , J Mann 1 , J Carlson 2 , C Brumme 3 , C Thobakgale 1 , P Goulder 4 , D Heckerman 2 , Z Brumme 3,5 , M Brockman 3,5 , and T Ndung’u 1 1 HIV Pathogenesis Prgm, Univ of KwaZulu-Natal, Durban, South Africa;; 2 Microsoft Res, Los Angeles, CA, US;; 3 BC Ctr for Excellence in HIV/ AIDS, Vancouver, Canada;; 4 Univ of Oxford, UK;; and 5 Simon Fraser Univ, Burnaby, Canada c Monday, 2:30-4 pm; Hall B2 Session 64–Poster Abstracts HIV Compartments 242 Andy Chevigne* 1 , V Fievez1 , S Delhalle1 , M Counson1 , J-M Plesseria1 , C Devaux1 , J-C Schmit1,2 , and S Deroo1 1 2 CRP-Sante, Luxembourg and Ctr Hosp de Luxembourg 243 on Magnetic Proteoliposomes Virginie Fievez* 1 , S Deroo1 , S Delhalle1 , J Mathu1 , F Martin1 , C Devaux1 , J-C Schmit1,2 , and A Chevigne1 252 Matthieu Perreau* 1 2 CRP Sante, Luxembourg and CHL, Luxembourg 1,2 , A-L Savoye1,2 , E De Crignis1,2 , J-M Corpataux1,2 , R Cubas3 , E Haddad3 , L De Leval1 , C Graziosi1,2 , and G Pantaleo1,2,4 1 2 Lausanne Univ Hosp, Switzerland;; Univ of Lausanne, Switzerland;; 3 4 Vaccine and Gene Therapy Inst of Florida, Port St Lucie, US;; and Swiss Vaccine Res Inst, Lausanne 253 Low-level HIV Plasma Viremia Is Rarely Due to Viral Infected Cells During Systemic Inflammation Marta Bull* 1,2 , C Mitchell1 , S Styrchak2 , J Soria3 , A LaRosa3 , E Ticona3 , J McKernan-Mullin2 , B Sorensen1 , R Coombs1 , and L Frenkel1,2 1 2 Univ of Washington, Seattle, US;; Seattle Childrens Res Inst, WA, US;; and 3Assn Civil Impacta Salud y Educacion, Lima, Peru <strong>Program</strong> 27 Poster Listings 254 Genital Tract Elena Dukhovlinova* 1,2 , J Anderson1,3,4 , D Moore2 , M Cohen1,4 , R Swanstrom1,4 , and Ctr for HIV/AIDS Vaccine Immunology Consortium 1 2 Univ of North Carolina Ctr for AIDS Res;; Univ of North Carolina Lineberger Comprehensive Cancer Ctr;; 3Bristol-Myers Squibb;; and 4Univ of North Carolina 255 M Surdo 1 , C Orlandi 2 , A Casabianca 2 , F Di Santo 1 , I Malet 3 , MF Cortese 1 , A-G Marcelin 3 , M Magnani 2 , C-F Perno 1,4 , and Francesca Ceccherini-Silberstein* 1 1 Univ of Rome Tor Vergata, Italy;; 2 Univ of Urbino Carlo Bo, Pesaro, Italy;; 3 Groupe Hosp Pitie-Salpetriere, UPMC Univ Paris 06, France;; and 4 INMI L Spallanzani, Rome, Italy 246 Kyle Nakamura* 1 , C Cerini1 , E Sobrera1 , L Heath2 , M Sinkala3 , C Kankasa4 , D Thea5 , J Mullins2 , L Kuhn6 , and G Aldrovandi1 1 2 Univ of Washington, Seattle, US;; 3 4 5 Lusaka District Hlth Mgmt Team, Zambia;; Univ of Zambia, Lusaka;; Boston Univ Sch of Publ Hlth, MA, US;; and 6Columbia Univ, New York, NY, US 247 Differentially Utilize CCR5 Zahra Parker* 1 , S Iyer1 , C Wilen1 , N Parrish1 , R Berro2 , B Lee3 , J Moore2 , G Shaw1 , B Hahn1 , and R Doms1,4 1 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; Weill Med Coll of Cornell Univ, New York, NY, US;; 3Univ of California, Los Angeles, US;; and 4 248 Throughput Receptor Affinity Profiling Kelechi Chikere* 1 , N Webb1 , T Chou1 , P Gorry2 , and B Lee1 1 2 Univ of California, Los Angeles, US and Burnet Inst, Melbourne, Australia 249 Divergent SIVsmm Strains Are Infectious and Replication Competent in vivo D Ma1 , H Li2 , C Xu1 , B Keele3 , J Estes3 , J Lifson3 , I Pandrea1 , G Shaw2 , B Hahn2 , and Cristian Apetrei* 1 1 2 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; and 3Frederick Natl Lab, MD, US 250 Virus Impact Clinical Outcome in Vaginal R5 SHIV Transmission Lily Tsai* 1 , I Tasovski2 , AR Leda1 , M Chin2 , and C Cheng-Mayer1 256 Evidence of Long-term Persistence of Human Effector 1 2 Aaron Diamond AIDS Res Ctr, New York, NY, US and Temple Univ Sch of Med, Philadelphia, PA, US + T Cells Using Replication-defective Integrated HIV-1 Provirus as a Genetic Marker Hiromi Imamichi* 1 , V Natarajan2 , T Imamichi2 , J Adelsberger2 , C Rehm1 , and C Lane1 1 2 NIAID, NIH, Bethesda, MD, US and SAIC-Frederick Inc, MD, US c Wednesday, 2:30-4 pm; Hall B2 Session 65–Poster Abstracts HIV Genotypes and Phenotypes 257 in HIV-1 Seroconverters from Different Risk Groups R McGovern1 , Z Brumme1,2 , C Johnson1 , R Hogg1,2 , E Wood1,3 , T Kerr1,3 , M Milloy1 , R Harrigan1,3 , Art Poon* 1,3 , and VANGUARD and VIDUS/ACCESS Cohort Studies 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; Simon Fraser Univ, Burnaby, Canada;; and 3Univ of British Columbia, Vancouver, Canada 258a with MTCT Li Yin* 1 , Y Cai1 , N Veras1 , K Chang1 , B Gardner1 , W Hou1 , K Nakamura2 , L Kuhn3 , G Aldrovandi2 , and M Goodenow1 1 2 Univ of Florida, Gainesville, US;; Los Angeles, CA, US;; and 3Columbia Univ, New York, NY, US 258b Viral Load Emma Hodcroft* 1 , E Fearnhill2 , A Phillips3 , D Dunn2 , D Pillay4 , J Hadfield5, A Leigh Brown1 , and UK HIV Drug Resistance Database 1 2 Univ of Edinburgh, Scotland;; MRC Clin Trials Unit, London, UK;; 3 4 5 Royal Free Hosp, London, UK;; Univ Coll London, UK;; and Univ of Oxford, UK 259 Martha Lewis* 1 , J de la Cruz1 , P Frohnen1 , H Ng1 , E Daar2 , and O Yang1 1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US and LA BioMed, Harbor UCLA Med Ctr, US 260 Become Viremic Controllers Xiaomei Kuang* 1 , A Le 1 , P Mwimanzi 1 , T Markle 1 , R Danroth 1 , T Ueno 2 , T Miura 3 , B Walker 4 , Z Brumme 1,5 , M Brockman 1,5 , and Acute HIV and Intl HIV Controllers Study Group 1 Simon Fraser Univ, Vancouver, Canada;; 2 Kumamoto Univ, Japan;; 3 Univ of Nagasaki, Japan;; 4 Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US;; and 5 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada
- Page 1 and 2: Pocket Program CR I 2O13 20th Confe
- Page 3 and 4: vi General Information CROI 2013 AB
- Page 5 and 6: viii General Information CROI 2013
- Page 7 and 8: x Hotel Information CROI 2013 Map K
- Page 9 and 10: CROI 2013 Session 2 j Sunday, 9 am-
- Page 11 and 12: CROI 2013 Session 8 i Monday, 8:30-
- Page 13 and 14: CROI 2013 Session 12 k Monday, 10 a
- Page 15 and 16: CROI 2013 Session 16 b Monday, 1:30
- Page 17 and 18: CROI 2013 Session 20 e Monday, 4-6
- Page 19 and 20: CROI 2013 Session 26 11:00 85 Impac
- Page 21 and 22: CROI 2013 Session 31 1023 Risk Fact
- Page 23 and 24: CROI 2013 Session 34 e Tuesday, 4-6
- Page 25 and 26: CROI 2013 Session 40 i Wednesday, 8
- Page 27 and 28: CROI 2013 Session 45 11:00 153LB Om
- Page 29 and 30: CROI 2013 Session 49 1103 Attrition
- Page 31 and 32: CROI 2013 Session 52 e Wednesday, 4
- Page 33: CROI 2013 Session 57 188LB Kelly
- Page 37 and 38: CROI 2013 Session 70 c Wednesday, 2
- Page 39 and 40: CROI 2013 Session 75 329 Impact of
- Page 41 and 42: CROI 2013 Session 82 369 Transcrip
- Page 43 and 44: CROI 2013 Session 89 413 Risk of Cl
- Page 45 and 46: CROI 2013 Session 93 456 A Longitud
- Page 47 and 48: CROI 2013 Session 100 c Tuesday, 2:
- Page 49 and 50: CROI 2013 Session 106 c Monday, 2:3
- Page 51 and 52: CROI 2013 Session 111 c Wednesday,
- Page 53 and 54: CROI 2013 Session 117 616 Immigran
- Page 55 and 56: CROI 2013 Session 122 656 Compariso
- Page 57 and 58: CROI 2013 Session 125 c Tuesday, 2:
- Page 59 and 60: CROI 2013 Session 131 c Monday, 2:3
- Page 61 and 62: CROI 2013 Session 137 c Tuesday, 2:
- Page 63 and 64: CROI 2013 Session 144 809 Prevalenc
- Page 65 and 66: CROI 2013 Session 150 847 Improving
- Page 67 and 68: CROI 2013 Session 161 885 The Impac
- Page 69 and 70: CROI 2013 Session 171 + 924 Women
- Page 71 and 72: CROI 2013 Session 180 c Wednesday,
- Page 73 and 74: CROI 2013 Session 187 994 Protecti
- Page 75 and 76: CROI 2013 Session 192 1032b Changes
- Page 77 and 78: CROI 2013 Session 197 1074 Alexa
- Page 79 and 80: CROI 2013 Session 199 nd 1113 -lin
- Page 81 and 82: POSTER SESSIONS Poster Hall open fr